Global Biomarker
Global Biomarker

Biomarker Comprehensive Study by Type (Safety Biomarkers, Efficacy Biomarkers (Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers), Validation Biomarkers), Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment, Others), Product (Consumables, Services, Software), Disease Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, Others) Players and Region - Global Market Outlook to 2025

Biomarker Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025 | CAGR: 13.6%  

Nov 2020 Edition 229 Pages 222 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Biomarker?
The high prevalence of cancer is encouraging research initiatives, driving the growth of the market. Extensive research and technological advancements used for the development of biomarker-based clinical diagnostics are projected to be the key contributors to the market. A rising number of Contract Research Organizations (CROs) is anticipated to further fuel the demand. Biomarkers which are also known as a molecular marker or signature molecule are used to check how the body responds to the treatment of any condition or disease. In simple words, they are used to examine organ functions and other health conditions. They are also used in imaging technology so that they can provide clear imaging of oncology tumors and other problems. They are also used in clinical studies to determine the effect and results of drugs in the early stage.

The market study is broken down by Type (Safety Biomarkers, Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers] and Validation Biomarkers), by Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment and Others) and major geographies with country level break-up. According to AMA, the Global Biomarker market is expected to see growth rate of 13.6%

The global biomarkers market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the biomarkers market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa. Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global Biomarker market throughout the predicted period.

QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (United States), Merck Millipore (United States), Bio-Rad Laboratories, Inc. (United States), Enzo Biochem, Inc. (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (United States), EKF Diagnostics (Germany) and Meso Scale Diagnostics, LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Signosis (Germany).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Biomarker market by Type, Application and Region.

On the basis of geography, the market of Biomarker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Product, the sub-segment i.e. Consumables will boost the Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Cancer will boost the Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In March 2020, F. Hoffmann-La Roche Ltd announced the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the Cobas 4800 HPV Test
In November 2019, Merck and Personalis, a cancer genomics company, entered into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck plans to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development


Market Trend
  • Increasing Number of Cros and Low Cost of Clinical Trials in Developing Countries
  • High Prevalence of Cancer

Market Drivers
  • Increasing diagnostic applications of biomarkers
  • Increasing R&D Funding for Pharma and Biotech Companies

Opportunities
  • Emerging Economies
  • New Initiatives for Biomarker Research

Restraints
  • High capital investments and low cost-benefit ratio
  • Poorly Suited Regulatory and Reimbursement Systems

Challenges
  • Proving the clinical validity in biomarker-based tests


Key Target Audience
Government Regulatory Bodies, Government Research Organization, Private Research Organization and Others

About Approach
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Safety Biomarkers
  • Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
  • Validation Biomarkers
By Application
  • Diagnostics
  • Personalized Medicine
  • Drug Discovery and Development
  • Disease Risk Assessment
  • Others
By Product
  • Consumables
  • Services
  • Software

By Disease Indication
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Immunological Disorders
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing diagnostic applications of biomarkers
      • 3.2.2. Increasing R&D Funding for Pharma and Biotech Companies
    • 3.3. Market Challenges
      • 3.3.1. Proving the clinical validity in biomarker-based tests
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Cros and Low Cost of Clinical Trials in Developing Countries
      • 3.4.2. High Prevalence of Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biomarker, by Type, Application, Product, Disease Indication and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Biomarker (Value)
      • 5.2.1. Global Biomarker by: Type (Value)
        • 5.2.1.1. Safety Biomarkers
        • 5.2.1.2. Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
        • 5.2.1.3. Validation Biomarkers
      • 5.2.2. Global Biomarker by: Application (Value)
        • 5.2.2.1. Diagnostics
        • 5.2.2.2. Personalized Medicine
        • 5.2.2.3. Drug Discovery and Development
        • 5.2.2.4. Disease Risk Assessment
        • 5.2.2.5. Others
      • 5.2.3. Global Biomarker by: Product (Value)
        • 5.2.3.1. Consumables
        • 5.2.3.2. Services
        • 5.2.3.3. Software
      • 5.2.4. Global Biomarker by: Disease Indication (Value)
        • 5.2.4.1. Cancer
        • 5.2.4.2. Neurological Disorders
        • 5.2.4.3. Cardiovascular Disorders
        • 5.2.4.4. Immunological Disorders
        • 5.2.4.5. Others
      • 5.2.5. Global Biomarker Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Biomarker (Price)
      • 5.3.1. Global Biomarker by: Type (Price)
  • 6. Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. QIAGEN N.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PerkinElmer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Millipore (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Enzo Biochem, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. EKF Diagnostics (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Meso Scale Diagnostics, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biomarker Sale, by Type, Application, Product, Disease Indication and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Biomarker (Value)
      • 7.2.1. Global Biomarker by: Type (Value)
        • 7.2.1.1. Safety Biomarkers
        • 7.2.1.2. Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
        • 7.2.1.3. Validation Biomarkers
      • 7.2.2. Global Biomarker by: Application (Value)
        • 7.2.2.1. Diagnostics
        • 7.2.2.2. Personalized Medicine
        • 7.2.2.3. Drug Discovery and Development
        • 7.2.2.4. Disease Risk Assessment
        • 7.2.2.5. Others
      • 7.2.3. Global Biomarker by: Product (Value)
        • 7.2.3.1. Consumables
        • 7.2.3.2. Services
        • 7.2.3.3. Software
      • 7.2.4. Global Biomarker by: Disease Indication (Value)
        • 7.2.4.1. Cancer
        • 7.2.4.2. Neurological Disorders
        • 7.2.4.3. Cardiovascular Disorders
        • 7.2.4.4. Immunological Disorders
        • 7.2.4.5. Others
      • 7.2.5. Global Biomarker Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Biomarker (Price)
      • 7.3.1. Global Biomarker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biomarker: by Type(USD Million)
  • Table 2. Biomarker Safety Biomarkers , by Region USD Million (2014-2019)
  • Table 3. Biomarker Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers] , by Region USD Million (2014-2019)
  • Table 4. Biomarker Validation Biomarkers , by Region USD Million (2014-2019)
  • Table 5. Biomarker: by Application(USD Million)
  • Table 6. Biomarker Diagnostics , by Region USD Million (2014-2019)
  • Table 7. Biomarker Personalized Medicine , by Region USD Million (2014-2019)
  • Table 8. Biomarker Drug Discovery and Development , by Region USD Million (2014-2019)
  • Table 9. Biomarker Disease Risk Assessment , by Region USD Million (2014-2019)
  • Table 10. Biomarker Others , by Region USD Million (2014-2019)
  • Table 11. Biomarker: by Product(USD Million)
  • Table 12. Biomarker Consumables , by Region USD Million (2014-2019)
  • Table 13. Biomarker Services , by Region USD Million (2014-2019)
  • Table 14. Biomarker Software , by Region USD Million (2014-2019)
  • Table 15. Biomarker: by Disease Indication(USD Million)
  • Table 16. Biomarker Cancer , by Region USD Million (2014-2019)
  • Table 17. Biomarker Neurological Disorders , by Region USD Million (2014-2019)
  • Table 18. Biomarker Cardiovascular Disorders , by Region USD Million (2014-2019)
  • Table 19. Biomarker Immunological Disorders , by Region USD Million (2014-2019)
  • Table 20. Biomarker Others , by Region USD Million (2014-2019)
  • Table 21. South America Biomarker, by Country USD Million (2014-2019)
  • Table 22. South America Biomarker, by Type USD Million (2014-2019)
  • Table 23. South America Biomarker, by Application USD Million (2014-2019)
  • Table 24. South America Biomarker, by Product USD Million (2014-2019)
  • Table 25. South America Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 26. Brazil Biomarker, by Type USD Million (2014-2019)
  • Table 27. Brazil Biomarker, by Application USD Million (2014-2019)
  • Table 28. Brazil Biomarker, by Product USD Million (2014-2019)
  • Table 29. Brazil Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 30. Argentina Biomarker, by Type USD Million (2014-2019)
  • Table 31. Argentina Biomarker, by Application USD Million (2014-2019)
  • Table 32. Argentina Biomarker, by Product USD Million (2014-2019)
  • Table 33. Argentina Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 34. Rest of South America Biomarker, by Type USD Million (2014-2019)
  • Table 35. Rest of South America Biomarker, by Application USD Million (2014-2019)
  • Table 36. Rest of South America Biomarker, by Product USD Million (2014-2019)
  • Table 37. Rest of South America Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 38. Asia Pacific Biomarker, by Country USD Million (2014-2019)
  • Table 39. Asia Pacific Biomarker, by Type USD Million (2014-2019)
  • Table 40. Asia Pacific Biomarker, by Application USD Million (2014-2019)
  • Table 41. Asia Pacific Biomarker, by Product USD Million (2014-2019)
  • Table 42. Asia Pacific Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 43. China Biomarker, by Type USD Million (2014-2019)
  • Table 44. China Biomarker, by Application USD Million (2014-2019)
  • Table 45. China Biomarker, by Product USD Million (2014-2019)
  • Table 46. China Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 47. Japan Biomarker, by Type USD Million (2014-2019)
  • Table 48. Japan Biomarker, by Application USD Million (2014-2019)
  • Table 49. Japan Biomarker, by Product USD Million (2014-2019)
  • Table 50. Japan Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 51. India Biomarker, by Type USD Million (2014-2019)
  • Table 52. India Biomarker, by Application USD Million (2014-2019)
  • Table 53. India Biomarker, by Product USD Million (2014-2019)
  • Table 54. India Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 55. South Korea Biomarker, by Type USD Million (2014-2019)
  • Table 56. South Korea Biomarker, by Application USD Million (2014-2019)
  • Table 57. South Korea Biomarker, by Product USD Million (2014-2019)
  • Table 58. South Korea Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 59. Taiwan Biomarker, by Type USD Million (2014-2019)
  • Table 60. Taiwan Biomarker, by Application USD Million (2014-2019)
  • Table 61. Taiwan Biomarker, by Product USD Million (2014-2019)
  • Table 62. Taiwan Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 63. Australia Biomarker, by Type USD Million (2014-2019)
  • Table 64. Australia Biomarker, by Application USD Million (2014-2019)
  • Table 65. Australia Biomarker, by Product USD Million (2014-2019)
  • Table 66. Australia Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Biomarker, by Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Biomarker, by Application USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Biomarker, by Product USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 71. Europe Biomarker, by Country USD Million (2014-2019)
  • Table 72. Europe Biomarker, by Type USD Million (2014-2019)
  • Table 73. Europe Biomarker, by Application USD Million (2014-2019)
  • Table 74. Europe Biomarker, by Product USD Million (2014-2019)
  • Table 75. Europe Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 76. Germany Biomarker, by Type USD Million (2014-2019)
  • Table 77. Germany Biomarker, by Application USD Million (2014-2019)
  • Table 78. Germany Biomarker, by Product USD Million (2014-2019)
  • Table 79. Germany Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 80. France Biomarker, by Type USD Million (2014-2019)
  • Table 81. France Biomarker, by Application USD Million (2014-2019)
  • Table 82. France Biomarker, by Product USD Million (2014-2019)
  • Table 83. France Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 84. Italy Biomarker, by Type USD Million (2014-2019)
  • Table 85. Italy Biomarker, by Application USD Million (2014-2019)
  • Table 86. Italy Biomarker, by Product USD Million (2014-2019)
  • Table 87. Italy Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 88. United Kingdom Biomarker, by Type USD Million (2014-2019)
  • Table 89. United Kingdom Biomarker, by Application USD Million (2014-2019)
  • Table 90. United Kingdom Biomarker, by Product USD Million (2014-2019)
  • Table 91. United Kingdom Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 92. Netherlands Biomarker, by Type USD Million (2014-2019)
  • Table 93. Netherlands Biomarker, by Application USD Million (2014-2019)
  • Table 94. Netherlands Biomarker, by Product USD Million (2014-2019)
  • Table 95. Netherlands Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 96. Rest of Europe Biomarker, by Type USD Million (2014-2019)
  • Table 97. Rest of Europe Biomarker, by Application USD Million (2014-2019)
  • Table 98. Rest of Europe Biomarker, by Product USD Million (2014-2019)
  • Table 99. Rest of Europe Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 100. MEA Biomarker, by Country USD Million (2014-2019)
  • Table 101. MEA Biomarker, by Type USD Million (2014-2019)
  • Table 102. MEA Biomarker, by Application USD Million (2014-2019)
  • Table 103. MEA Biomarker, by Product USD Million (2014-2019)
  • Table 104. MEA Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 105. Middle East Biomarker, by Type USD Million (2014-2019)
  • Table 106. Middle East Biomarker, by Application USD Million (2014-2019)
  • Table 107. Middle East Biomarker, by Product USD Million (2014-2019)
  • Table 108. Middle East Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 109. Africa Biomarker, by Type USD Million (2014-2019)
  • Table 110. Africa Biomarker, by Application USD Million (2014-2019)
  • Table 111. Africa Biomarker, by Product USD Million (2014-2019)
  • Table 112. Africa Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 113. North America Biomarker, by Country USD Million (2014-2019)
  • Table 114. North America Biomarker, by Type USD Million (2014-2019)
  • Table 115. North America Biomarker, by Application USD Million (2014-2019)
  • Table 116. North America Biomarker, by Product USD Million (2014-2019)
  • Table 117. North America Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 118. United States Biomarker, by Type USD Million (2014-2019)
  • Table 119. United States Biomarker, by Application USD Million (2014-2019)
  • Table 120. United States Biomarker, by Product USD Million (2014-2019)
  • Table 121. United States Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 122. Canada Biomarker, by Type USD Million (2014-2019)
  • Table 123. Canada Biomarker, by Application USD Million (2014-2019)
  • Table 124. Canada Biomarker, by Product USD Million (2014-2019)
  • Table 125. Canada Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 126. Mexico Biomarker, by Type USD Million (2014-2019)
  • Table 127. Mexico Biomarker, by Application USD Million (2014-2019)
  • Table 128. Mexico Biomarker, by Product USD Million (2014-2019)
  • Table 129. Mexico Biomarker, by Disease Indication USD Million (2014-2019)
  • Table 130. Biomarker: by Type(USD/Units)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Biomarker: by Type(USD Million)
  • Table 142. Biomarker Safety Biomarkers , by Region USD Million (2020-2025)
  • Table 143. Biomarker Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers] , by Region USD Million (2020-2025)
  • Table 144. Biomarker Validation Biomarkers , by Region USD Million (2020-2025)
  • Table 145. Biomarker: by Application(USD Million)
  • Table 146. Biomarker Diagnostics , by Region USD Million (2020-2025)
  • Table 147. Biomarker Personalized Medicine , by Region USD Million (2020-2025)
  • Table 148. Biomarker Drug Discovery and Development , by Region USD Million (2020-2025)
  • Table 149. Biomarker Disease Risk Assessment , by Region USD Million (2020-2025)
  • Table 150. Biomarker Others , by Region USD Million (2020-2025)
  • Table 151. Biomarker: by Product(USD Million)
  • Table 152. Biomarker Consumables , by Region USD Million (2020-2025)
  • Table 153. Biomarker Services , by Region USD Million (2020-2025)
  • Table 154. Biomarker Software , by Region USD Million (2020-2025)
  • Table 155. Biomarker: by Disease Indication(USD Million)
  • Table 156. Biomarker Cancer , by Region USD Million (2020-2025)
  • Table 157. Biomarker Neurological Disorders , by Region USD Million (2020-2025)
  • Table 158. Biomarker Cardiovascular Disorders , by Region USD Million (2020-2025)
  • Table 159. Biomarker Immunological Disorders , by Region USD Million (2020-2025)
  • Table 160. Biomarker Others , by Region USD Million (2020-2025)
  • Table 161. South America Biomarker, by Country USD Million (2020-2025)
  • Table 162. South America Biomarker, by Type USD Million (2020-2025)
  • Table 163. South America Biomarker, by Application USD Million (2020-2025)
  • Table 164. South America Biomarker, by Product USD Million (2020-2025)
  • Table 165. South America Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 166. Brazil Biomarker, by Type USD Million (2020-2025)
  • Table 167. Brazil Biomarker, by Application USD Million (2020-2025)
  • Table 168. Brazil Biomarker, by Product USD Million (2020-2025)
  • Table 169. Brazil Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 170. Argentina Biomarker, by Type USD Million (2020-2025)
  • Table 171. Argentina Biomarker, by Application USD Million (2020-2025)
  • Table 172. Argentina Biomarker, by Product USD Million (2020-2025)
  • Table 173. Argentina Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 174. Rest of South America Biomarker, by Type USD Million (2020-2025)
  • Table 175. Rest of South America Biomarker, by Application USD Million (2020-2025)
  • Table 176. Rest of South America Biomarker, by Product USD Million (2020-2025)
  • Table 177. Rest of South America Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 178. Asia Pacific Biomarker, by Country USD Million (2020-2025)
  • Table 179. Asia Pacific Biomarker, by Type USD Million (2020-2025)
  • Table 180. Asia Pacific Biomarker, by Application USD Million (2020-2025)
  • Table 181. Asia Pacific Biomarker, by Product USD Million (2020-2025)
  • Table 182. Asia Pacific Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 183. China Biomarker, by Type USD Million (2020-2025)
  • Table 184. China Biomarker, by Application USD Million (2020-2025)
  • Table 185. China Biomarker, by Product USD Million (2020-2025)
  • Table 186. China Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 187. Japan Biomarker, by Type USD Million (2020-2025)
  • Table 188. Japan Biomarker, by Application USD Million (2020-2025)
  • Table 189. Japan Biomarker, by Product USD Million (2020-2025)
  • Table 190. Japan Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 191. India Biomarker, by Type USD Million (2020-2025)
  • Table 192. India Biomarker, by Application USD Million (2020-2025)
  • Table 193. India Biomarker, by Product USD Million (2020-2025)
  • Table 194. India Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 195. South Korea Biomarker, by Type USD Million (2020-2025)
  • Table 196. South Korea Biomarker, by Application USD Million (2020-2025)
  • Table 197. South Korea Biomarker, by Product USD Million (2020-2025)
  • Table 198. South Korea Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 199. Taiwan Biomarker, by Type USD Million (2020-2025)
  • Table 200. Taiwan Biomarker, by Application USD Million (2020-2025)
  • Table 201. Taiwan Biomarker, by Product USD Million (2020-2025)
  • Table 202. Taiwan Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 203. Australia Biomarker, by Type USD Million (2020-2025)
  • Table 204. Australia Biomarker, by Application USD Million (2020-2025)
  • Table 205. Australia Biomarker, by Product USD Million (2020-2025)
  • Table 206. Australia Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 207. Rest of Asia-Pacific Biomarker, by Type USD Million (2020-2025)
  • Table 208. Rest of Asia-Pacific Biomarker, by Application USD Million (2020-2025)
  • Table 209. Rest of Asia-Pacific Biomarker, by Product USD Million (2020-2025)
  • Table 210. Rest of Asia-Pacific Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 211. Europe Biomarker, by Country USD Million (2020-2025)
  • Table 212. Europe Biomarker, by Type USD Million (2020-2025)
  • Table 213. Europe Biomarker, by Application USD Million (2020-2025)
  • Table 214. Europe Biomarker, by Product USD Million (2020-2025)
  • Table 215. Europe Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 216. Germany Biomarker, by Type USD Million (2020-2025)
  • Table 217. Germany Biomarker, by Application USD Million (2020-2025)
  • Table 218. Germany Biomarker, by Product USD Million (2020-2025)
  • Table 219. Germany Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 220. France Biomarker, by Type USD Million (2020-2025)
  • Table 221. France Biomarker, by Application USD Million (2020-2025)
  • Table 222. France Biomarker, by Product USD Million (2020-2025)
  • Table 223. France Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 224. Italy Biomarker, by Type USD Million (2020-2025)
  • Table 225. Italy Biomarker, by Application USD Million (2020-2025)
  • Table 226. Italy Biomarker, by Product USD Million (2020-2025)
  • Table 227. Italy Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 228. United Kingdom Biomarker, by Type USD Million (2020-2025)
  • Table 229. United Kingdom Biomarker, by Application USD Million (2020-2025)
  • Table 230. United Kingdom Biomarker, by Product USD Million (2020-2025)
  • Table 231. United Kingdom Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 232. Netherlands Biomarker, by Type USD Million (2020-2025)
  • Table 233. Netherlands Biomarker, by Application USD Million (2020-2025)
  • Table 234. Netherlands Biomarker, by Product USD Million (2020-2025)
  • Table 235. Netherlands Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 236. Rest of Europe Biomarker, by Type USD Million (2020-2025)
  • Table 237. Rest of Europe Biomarker, by Application USD Million (2020-2025)
  • Table 238. Rest of Europe Biomarker, by Product USD Million (2020-2025)
  • Table 239. Rest of Europe Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 240. MEA Biomarker, by Country USD Million (2020-2025)
  • Table 241. MEA Biomarker, by Type USD Million (2020-2025)
  • Table 242. MEA Biomarker, by Application USD Million (2020-2025)
  • Table 243. MEA Biomarker, by Product USD Million (2020-2025)
  • Table 244. MEA Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 245. Middle East Biomarker, by Type USD Million (2020-2025)
  • Table 246. Middle East Biomarker, by Application USD Million (2020-2025)
  • Table 247. Middle East Biomarker, by Product USD Million (2020-2025)
  • Table 248. Middle East Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 249. Africa Biomarker, by Type USD Million (2020-2025)
  • Table 250. Africa Biomarker, by Application USD Million (2020-2025)
  • Table 251. Africa Biomarker, by Product USD Million (2020-2025)
  • Table 252. Africa Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 253. North America Biomarker, by Country USD Million (2020-2025)
  • Table 254. North America Biomarker, by Type USD Million (2020-2025)
  • Table 255. North America Biomarker, by Application USD Million (2020-2025)
  • Table 256. North America Biomarker, by Product USD Million (2020-2025)
  • Table 257. North America Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 258. United States Biomarker, by Type USD Million (2020-2025)
  • Table 259. United States Biomarker, by Application USD Million (2020-2025)
  • Table 260. United States Biomarker, by Product USD Million (2020-2025)
  • Table 261. United States Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 262. Canada Biomarker, by Type USD Million (2020-2025)
  • Table 263. Canada Biomarker, by Application USD Million (2020-2025)
  • Table 264. Canada Biomarker, by Product USD Million (2020-2025)
  • Table 265. Canada Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 266. Mexico Biomarker, by Type USD Million (2020-2025)
  • Table 267. Mexico Biomarker, by Application USD Million (2020-2025)
  • Table 268. Mexico Biomarker, by Product USD Million (2020-2025)
  • Table 269. Mexico Biomarker, by Disease Indication USD Million (2020-2025)
  • Table 270. Biomarker: by Type(USD/Units)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biomarker: by Type USD Million (2014-2019)
  • Figure 5. Global Biomarker: by Application USD Million (2014-2019)
  • Figure 6. Global Biomarker: by Product USD Million (2014-2019)
  • Figure 7. Global Biomarker: by Disease Indication USD Million (2014-2019)
  • Figure 8. South America Biomarker Share (%), by Country
  • Figure 9. Asia Pacific Biomarker Share (%), by Country
  • Figure 10. Europe Biomarker Share (%), by Country
  • Figure 11. MEA Biomarker Share (%), by Country
  • Figure 12. North America Biomarker Share (%), by Country
  • Figure 13. Global Biomarker: by Type USD/Units (2014-2019)
  • Figure 14. Global Biomarker share by Players 2019 (%)
  • Figure 15. Global Biomarker share by Players (Top 3) 2019(%)
  • Figure 16. Global Biomarker share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. QIAGEN N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. QIAGEN N.V. (Netherlands) Revenue: by Geography 2019
  • Figure 20. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. PerkinElmer, Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Merck Millipore (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck Millipore (United States) Revenue: by Geography 2019
  • Figure 24. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Enzo Biochem, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Enzo Biochem, Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2019
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2019
  • Figure 32. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 34. EKF Diagnostics (Germany) Revenue, Net Income and Gross profit
  • Figure 35. EKF Diagnostics (Germany) Revenue: by Geography 2019
  • Figure 36. Meso Scale Diagnostics, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 37. Meso Scale Diagnostics, LLC (United States) Revenue: by Geography 2019
  • Figure 38. Global Biomarker: by Type USD Million (2020-2025)
  • Figure 39. Global Biomarker: by Application USD Million (2020-2025)
  • Figure 40. Global Biomarker: by Product USD Million (2020-2025)
  • Figure 41. Global Biomarker: by Disease Indication USD Million (2020-2025)
  • Figure 42. South America Biomarker Share (%), by Country
  • Figure 43. Asia Pacific Biomarker Share (%), by Country
  • Figure 44. Europe Biomarker Share (%), by Country
  • Figure 45. MEA Biomarker Share (%), by Country
  • Figure 46. North America Biomarker Share (%), by Country
  • Figure 47. Global Biomarker: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • QIAGEN N.V. (Netherlands)
  • PerkinElmer, Inc. (United States)
  • Merck Millipore (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Enzo Biochem, Inc. (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott Laboratories (United States)
  • EKF Diagnostics (Germany)
  • Meso Scale Diagnostics, LLC (United States)
Additional players considered in the study are as follows:
Signosis (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation